Keith W Rickert
Overview
Explore the profile of Keith W Rickert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Layman H, Rickert K, Wilson S, Aksyuk A, Dunty J, Natrakul D, et al.
PLoS One
. 2020 Mar;
15(3):e0229672.
PMID: 32214362
More than 170 types of human papilloma viruses (HPV) exist with many causing proliferative diseases linked to malignancy in indications such as cervical cancer and head and neck squamous cell...
2.
Li Q, Peterson N, Hanna R, Kuszpit K, White J, Allen K, et al.
Mol Pharm
. 2019 Dec;
17(2):507-516.
PMID: 31841002
Targeted strategies to deliver and retain drugs to kidneys are needed to improve drug accumulation and efficacy in a myriad of kidney diseases. These drug delivery systems show potential for...
3.
Cannon D, Shan L, Du Q, Shirinian L, Rickert K, Rosenthal K, et al.
PLoS Comput Biol
. 2019 May;
15(5):e1006980.
PMID: 31042706
Antibodies are an important class of therapeutics that have significant clinical impact for the treatment of severe diseases. Computational tools to support antibody drug discovery have been developing at an...
4.
Li Q, Barrett A, Vijayakrishnan B, Tiberghien A, Beard R, Rickert K, et al.
Bioconjug Chem
. 2019 Mar;
30(4):1232-1243.
PMID: 30912649
Despite some clinical success with antibody-drug conjugates (ADCs) in patients with solid tumors and hematological malignancies, improvements in ADC design are still desirable due to the narrow therapeutic window of...
5.
Marchetti G, Burwell T, Peterson N, Cann J, Hanna R, Li Q, et al.
Commun Biol
. 2019 Mar;
2:92.
PMID: 30854484
Systemic administration of bio-therapeutics can result in only a fraction of drug reaching targeted tissues, with the majority of drug being distributed to tissues irrelevant to the drug's site of...
6.
Li Q, White J, Peterson N, Rickert K, Lloyd C, Allen K, et al.
J Control Release
. 2018 Apr;
279:126-135.
PMID: 29653224
The accumulation, dissemination and clearance of monoclonal antibody-based therapeutics or imaging reagents targeting tumor associated antigens is governed by several factors including affinity, size, charge, and valency. Tumor targeting antibody...
7.
Novarra S, Grinberg L, Rickert K, Barnes A, Wilson S, Baca M
MAbs
. 2016 May;
8(6):1118-25.
PMID: 27210548
Fusion of proteins to the Fc region of IgG is widely used to express cellular receptors and other extracellular proteins, but cleavage of the fusion partner is sometimes required for...
8.
Kutilek V, Andrews C, Richards M, Xu Z, Sun T, Chen Y, et al.
J Biomol Screen
. 2016 Mar;
21(6):608-19.
PMID: 26969322
The primary objective of early drug discovery is to associate druggable target space with a desired phenotype. The inability to efficiently associate these often leads to failure early in the...
9.
Rickert K, Grinberg L, Woods R, Wilson S, Bowen M, Baca M
MAbs
. 2016 Feb;
8(3):501-12.
PMID: 26852694
The enormous diversity created by gene recombination and somatic hypermutation makes de novo protein sequencing of monoclonal antibodies a uniquely challenging problem. Modern mass spectrometry-based sequencing will rarely, if ever,...
10.
Allen S, Parthasarathy G, Darke P, Diehl R, Ford R, Hall D, et al.
J Biol Chem
. 2015 Jul;
290(33):20360-73.
PMID: 26134571
G-protein-coupled receptor (GPCR) kinases (GRKs) bind to and phosphorylate GPCRs, initiating the process of GPCR desensitization and internalization. GRK4 is implicated in the regulation of blood pressure, and three GRK4...